Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Enzyme Replacement Therapy Market
Enzyme Replacement Therapy Market Share
- Report ID: GMI6680
- Published Date: Sep 2023
- Report Format: PDF
Enzyme Replacement Therapy Market Share
The well known, established, prominent players in enzyme replacement therapy market are:
- Sanofi
- Biomarin Pharmaceutical Inc
- AbbVie Inc
- Pfizer, Inc
- Alexion Pharmaceuticals Inc
- Allergan plc
- Horizon Pharma Public Limited Company
- Recordati Rare Diseases
- Protalix Biotherapeutics
- Amicus Therapeutics
Frequently Asked Questions (FAQ) :
Global market size for enzyme replacement therapy (ERT) was valued at USD 10 billion in 2023 and is expected to reach USD 18.6 billion by 2032, backed by the rising prevalence of rare genetic disorders, including LSDs such as gaucher disease, fabry disease, pompe disease, and mucopolysaccharidosis (MPS).
The agalsidase beta segment accounted for 8.7% market share in 2022 as the enzyme demonstrates efficacy in reducing the accumulation of Gb3 and related substances in various organs and tissues.
North America market is expected to record a CAGR of 7.2% from 2023-2032 as the region has a relatively high prevalence of rare genetic disorders, including Gaucher disease, Fabry disease, Pompe disease, and mucopolysaccharidosis (MPS).
Sanofi, Biomarin Pharmaceutical Inc., AbbVie Inc., Pfizer, Inc., Alexion Pharmaceuticals Inc., Allergan plc, Horizon Pharma Public Limited Company, Recordati Rare Diseases, Protalix Biotherapeutics, and Amicus Therapeutics, Inc.
Enzyme Replacement Therapy Market Scope
×
Get a free sample of
Enzyme Replacement Therapy Market
Inquiry Before Buying
Get special pricing options on this report
Request Sectional Data
Over 70% of our clients customize reports to fit their needs. Please tell us how you would like to customize yours
below